| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0959-8049(00)00080-0 |
| P698 | PubMed publication ID | 10908843 |
| P2093 | author name string | H von der Maase | |
| P2860 | cites work | Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 |
| Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | Q33331273 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience | Q33376563 | ||
| Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer | Q33501053 | ||
| A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer | Q68891233 | ||
| Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience | Q69654530 | ||
| Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma | Q73181726 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| P921 | main subject | cisplatin | Q412415 |
| P304 | page(s) | 13-16 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer | |
| P478 | volume | 36 Suppl 2 |
| Q90292380 | A new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy |
| Q34850202 | Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity |
| Q43137449 | Cerebral vasculitis associated with gemcitabine |
| Q94538461 | Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma |
| Q37787341 | Intravesical drug delivery: Challenges, current status, opportunities and novel strategies |
| Q36619428 | State-of-the-art management of metastatic disease at initial presentation or recurrence |
Search more.